Immunosuppressive macrophages determine the effect of cellular senescence on tumor progression


Por: Lalinde-Gutiérrez, M, Pérez-Ramos, S, Rodilla, V, Garcia-Baucells, P, Perera-Bel, J, Berenguer-Molins, P, Nonell, L, Agustí-Barea, I, George, C and Arribas, J

Publicada: 1 ene 2026
Resumen:
Cells terminally arrested in the cell cycle that exhibit a distinct secretory phenotype are referred to as senescent. These cells play a complex role during tumor progression; they can inhibit or promote tumor growth depending on disease stage. We developed a mouse model that allows monitoring and selective elimination of cells expressing high levels of the cyclin-dependent kinase inhibitor p16 and interleukin-6. These mice, termed SuSe (suicidal senescence), were crossed with the mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) model of breast cancer. Functional characterization in SuSe/PyMT mice confirmed that depletion of senescent cells (senolysis) in early and late lesions accelerated and decelerated tumor growth and metastasis, respectively. Tumor acceleration was attributed to expansion of immunosuppressive, protumorigenic macrophages. C-C motif chemokine ligand 2 was identified as an autocrine chemokine essential for their recruitment and maintenance. Depletion of these macrophages reversed the effects of senescent cell clearance, rendering senolysis antitumorigenic even at early stages. Our results suggest that targeting immunosuppressive macrophages can preserve the benefits of senolysis while mitigating adverse effects.

Filiaciones:
Lalinde-Gutiérrez, M:
 Vall dHebron Inst Oncol VHIO, Preclin & Translat Res Program, Barcelona 08035, Spain

 Hosp Mar Med Res Inst HMRI, Canc Res Program, Barcelona 08003, Spain

Pérez-Ramos, S:
 Vall dHebron Inst Oncol VHIO, Preclin & Translat Res Program, Barcelona 08035, Spain

:
 Vall dHebron Inst Oncol VHIO, Preclin & Translat Res Program, Barcelona 08035, Spain

 Josep Carreras Leukaemia Res Inst IJC, Badalona 08916, Spain

Garcia-Baucells, P:
 Hosp Mar Med Res Inst HMRI, Canc Res Program, Barcelona 08003, Spain

Perera-Bel, J:
 Hosp Mar Res Inst HMRI, Bioinformat Unit, MARData, Barcelona, Spain

Berenguer-Molins, P:
 Hosp Mar Res Inst HMRI, Bioinformat Unit, MARData, Barcelona, Spain

Nonell, L:
 Vall dHebron Inst Oncol VHIO, Bioinformat Unit, Barcelona 08035, Spain

Agustí-Barea, I:
 Vall dHebron Inst Oncol VHIO, Bioinformat Unit, Barcelona 08035, Spain

George, C:
 Hosp Mar Med Res Inst HMRI, Canc Res Program, Barcelona 08003, Spain

Arribas, J:
 Vall dHebron Inst Oncol VHIO, Preclin & Translat Res Program, Barcelona 08035, Spain

 Hosp Mar Med Res Inst HMRI, Canc Res Program, Barcelona 08003, Spain

 Ctr Invest Biomed Red Canc, Madrid 28029, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona 08010, Spain
ISSN: 23752548





Science Advances
Editorial
American Association for the Advancement of Science, 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 12 Número: 1
Páginas:
WOS Id: 001652043900012
ID de PubMed: 41477861
imagen Green Submitted, gold

MÉTRICAS